Purpura fulminans is an acute purpuric rash characterized by coagulation of the microvasculature, which leads to purpuric lesions and skin necrosis. It is a true dermatological emergency and requires immediate diagnosis and management. Patients are often acutely ill with fever, have hemorrhage from multiple sites, and may be hypotensive. It is rapidly progressive and is often accompanied by disseminated intravascular coagulation and circulatory collapse. It occurs in neonates, children, and adults. There are 3 forms of this disease with a classification scheme based on the triggering mechanism. The mortality rate has been decreasing with supportive care, improved management of secondary complications, and some targeted treatments, but it remains a disabling condition often resulting in major amputations in those who survive.
Purpura fulminans is a rapidly evolving syndrome of skin microvascular thrombosis and hemorrhagic necrosis. It is considered a sign of certain systemic diseases rather than a disease unto itself. The 3 types of purpura fulminans are neonatal, idiopathic, and acute infectious. Neonatal purpura fulminans is associated with a hereditary deficiency of the anticoagulants protein C, protein S, and antithrombin III. It manifests very early in life and treatment is aimed at these deficiencies.  Idiopathic purpura fulminans is thought to be a post-infectious autoimmune disorder often following an initiating febrile illness, which later leads to rapidly progressive purpura. In this form, a relative deficiency of protein S is believed to be causative. Acute infectious purpura fulminans is the third and most common type. It manifests as a skin finding in the most severe septic patients as well as in necrotizing fasciitis with a predilection to certain infectious agents.
First described in 1884, purpura fulminans remains a relatively rare disease, and thus, most of the articles written about it are case reports and case series. Each form of purpura fulminans has a different prevalence. The hereditary neonatal form with severe protein C deficiency occurs in about 1:1,000,000 live births. Acute infectious purpura fulminans can be seen in up to 10% to 20% of patients who develop meningococcal septicemia. Meningococcus and Streptococcus pneumoniae were identified as the most common bacterial triggers, and varicella was the most common viral trigger. Acute infectious purpura fulminans has been found to be more common in patients who are physically or functionally asplenic. The idiopathic post-infectious form is very rare with only a few hundred cases reported.
Purpura fulminans is the acute onset of often rapidly progressing cutaneous hemorrhage and necrosis caused by dermal vascular thrombosis and disseminated intravascular necrosis. It occurs in 3 clinical settings:
All types of purpura fulminans involve dysfunction of hemostasis with a shift to a disease state with overwhelming procoagulation.
Neonatal purpura fulminans is associated with a hereditary deficiency of the anticoagulants protein C and S. These proteins are vitamin-K dependent cofactors which are pro-fibrinolytic. Protein C is one of the major inhibitors of the coagulation system which when activated inhibits factor Va and VIIIa which in turn down-regulate thrombin synthesis. Neonates typically present with massive venous and arterial thrombosis of the skin and other organs within 5 days of birth.
Acute infectious purpura fulminans is the most common type and is associated with an acquired deficiency of protein C. The mechanism involves a disruption of the coagulation balance. Bacterial endotoxin triggers consumption of proteins C and S and antithrombin III. This pro-coagulative state leads to thromboses of dermal vessels and is associated with disseminated intravascular coagulation. The skin lesions may present early as petechial rashes. These rapidly progress to larger ecchymotic areas. Later in the course, hemorrhagic bullae may form which contribute to the classic hard eschars characteristic of purpura fulminans.
Idiopathic purpura fulminans, the rarest form of the disease, has been associated with the development of anti-protein S antibodies. These antibodies bind to protein S and get excreted. This causes to a transient protein S deficiency which leads to hypo-activation of the protein C pathway and a hypercoagulable state similar to what was described above.
The skin findings of purpura fulminans have a characteristic appearance and evolution. Purpura fulminans begins with erythema, which develops irregular central areas of blue-black hemorrhagic necrosis. In some cases, vesicles and bulla form. The affected skin initially is painful and indurated, but in the later stages, there may be a total loss of sensation. Secondary infection of gangrenous tissue may occur. Necrosis may extend to deeper tissues.
In general, the history and physical exam for purpura fulminans should be aimed at early recognition and determination of the underlying cause. Make sure to thoroughly examine the patient’s skin, especially in patients who could be presenting with necrotizing fasciitis. Early in the diagnosis of associated diseases, the skin findings may be subtle, so it is important to keep this diagnosis in your differential. Petechial rash or bruising in a neonate or septic patient should trigger consideration of purpura fulminans. Components of a patient’s history include a history of severe infections or trauma as well previous splenectomy. Because of the association with DIC patients may experience bleeding from multiple sites including mucous membranes, areas of trauma or the rectum. Because of the association with severe septic shock, the patient may experience symptoms of end-organ damage such as hematuria, oliguria, and respiratory distress. Pain out of proportion to exam should always make one consider necrotizing fasciitis.
As noted above, this disease represents an imbalance in the coagulation system. Specific levels of antithrombin III, free protein C, and free and total protein S may help confirm the diagnosis especially in the neonatal form of the disease. Otherwise, the evaluation of patients with purpura fulminans mimics the evaluation of the underlying cause. Searching for inciting infection with labs, cultures, and imaging should follow sepsis guidelines. If the clinician is considering necrotizing fasciitis, white blood cell (WBC) count and a sodium level with or without the other components of the LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score may help the surgeon decide on an early intervention. Because of the strong association with disseminated intravascular coagulation, one should also evaluate for thrombocytopenia, elevated coagulation factors (PT, PTT), increased d-dimer assay (or serum fibrin degradation products), and a decreasing fibrinogen level.
The treatment of all types of purpura fulminans starts with supportive care and adequate hydration. This is important because of the widespread thrombosis associated with this disease can lead to damage of multiple end organs. As this commences, finding and treating the underlying cause is essential. Anticoagulation may be stared to prevent further necrosis. There may need for replacement of blood, factors, and platelets lost because of both the pro-coagulable state and DIC. Finally, early surgical debridement for areas which have become necrotic has been shown to decrease mortality.
In the neonatal form of the disease hydration, platelet transfusion, followed by an assessment of protein C and S levels followed closely with fresh frozen plasma transfusions are the mainstay of treatment. Heparin and warfarin have been used as anticoagulants, and later protein C concentrate can be added if this deficiency is found. 
The treatment of idiopathic purpura fulminans is similar to what is described above. Additionally, there may be a role for immunomodulation with corticosteroids.
In the acute infectious form, broad-spectrum antibiotics should include coverage of Neisseria meningitidis, Streptococcus, Staphylococcus, and Clostridia species. Often carbapenem or vancomycin with beta lactam-beta lactamase inhibitor combinations are used. Clindamycin is often included as it has specific properties which inhibit some of the toxins which allow this disease to progress. IVIg therapy is also used because of antibodies to these toxins. Activated protein C may be administered to reduce the inflammatory cascade, restore the coagulation balance which may decrease the progression of purpuric skin injury. In acute infectious purpura fulminans, the decision to anticoagulated is based on the occurrence of concurrent DIC.
In all forms of the disease repeated tissue assessments with debridement of affected areas are carried out as needed. Repeated surgeries are often required.
|||Neonatal Purpura Fulminans, a rare genetic disorder due to protein C deficiency: A case report., Irfan Kazi SG,Siddiqui E,Habib I,Tabassum S,Afzal B,Khan IQ,, JPMA. The Journal of the Pakistan Medical Association, 2018 Mar [PubMed PMID: 29540887]|
|||Lamadrid-Zertuche AC,Garza-Rodríguez V,Ocampo-Candiani JJ, Pigmented purpura and cutaneous vascular occlusion syndromes. Anais brasileiros de dermatologia. 2018 Jun [PubMed PMID: 29924250]|
|||Findley T,Patel M,Chapman J,Brown D,Duncan AF, Acquired Versus Congenital Neonatal Purpura Fulminans: A Case Report and Literature Review. Journal of pediatric hematology/oncology. 2018 Nov [PubMed PMID: 29683961]|
|||Hale AJ,LaSalvia M,Kirby JE,Kimball A,Baden R, Fatal purpura fulminans and Waterhouse-Friderichsen syndrome from fulminant Streptococcus pneumoniae sepsis in an asplenic young adult. IDCases. 2016 [PubMed PMID: 27583208]|
|||Idiopathic purpura fulminans., Bektas F,Soyuncu S,, The American journal of emergency medicine, 2011 May [PubMed PMID: 20674230]|
|||Purpura fulminans - It's Not Always Sepsis., Olivieri M,Huetker S,Kurnik K,Bidlingmaier C,Keil J,Reiter K,Hoffmann F,, Klinische Padiatrie, 2018 Jan 30 [PubMed PMID: 29381878]|
|||Homozygous protein C deficiency presenting as neonatal purpura fulminans: management with fresh frozen plasma, low molecular weight heparin and protein C concentrate., Kizilocak H,Ozdemir N,Dikme G,Koc B,Celkan T,, Journal of thrombosis and thrombolysis, 2018 Feb [PubMed PMID: 29270858]|
|||Purpura Fulminans: Mechanism and Management of Dysregulated Hemostasis., Colling ME,Bendapudi PK,, Transfusion medicine reviews, 2018 Apr [PubMed PMID: 29157918]|
|||Modern concepts of the diagnosis and treatment of purpura fulminans., Edlich RF,Cross CL,Dahlstrom JJ,Long WB 3rd,, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2008 [PubMed PMID: 18652566]|